AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
暂无分享,去创建一个
E. Lobenhofer | M. Friedrich | T. Raum | A. Coxon | J. Canon | M. Giffin | O. Homann | C. Murawsky | J. Werner | P. Deegen | S. Caenepeel | Yajing Yang | J. Bailis | J. Pearson | J. Estrada | P. Beltran | P. Hughes | K. Cooke | Siyuan Liu | J. Zhan | F. Lee | J. Stevens | Melissa Thomas | Jennitte L Stevens | Tobias Raum | Petra Deegen | Juan Estrada
[1] H. Einsele,et al. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Lassmann,et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. , 2019, Cancer research.
[3] C. Rudin,et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.
[4] G. Gelbrich,et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. , 2019, Blood advances.
[5] T. Cloughesy,et al. Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease. , 2019, Journal of Clinical Oncology.
[6] R. Govindan,et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Gettinger,et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331 , 2018, Annals of Oncology.
[8] M. Hellmann,et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[10] Ramsis Benjamin,et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors , 2018, Annals of Hematology.
[11] FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer , 2018, Case Medical Research.
[12] D. Atanackovic,et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors , 2018, Oncoimmunology.
[13] G. Freeman,et al. Role of PD-1 during effector CD8 T cell differentiation , 2018, Proceedings of the National Academy of Sciences.
[14] H. Dombret,et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.
[15] A. Wolf,et al. Blinatumomab Pharmacodynamics and Exposure–Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia , 2018, Journal of clinical pharmacology.
[16] W. Weichert,et al. Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors. , 2018, Endocrine-related cancer.
[17] J. Minna,et al. Small-cell lung cancer: what we know, what we need to know and the path forward , 2017, Nature Reviews Cancer.
[18] P. Ott,et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Rudin,et al. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. , 2017, Cancer research.
[20] J. Albanell,et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). , 2017 .
[21] C. Rudin,et al. Unravelling the biology of SCLC: implications for therapy , 2017, Nature Reviews Clinical Oncology.
[22] W. Klapper,et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.
[23] Weiqi Wang,et al. Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability* , 2016, The Journal of Biological Chemistry.
[24] Lai Xu,et al. Correlation of transferrin receptor (CD71) with Ki67 expression on stimulated human and mouse T cells: The kinetics of expression of T cell activation markers. , 2016, Journal of immunological methods.
[25] M. Ebinger,et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts , 2016, Oncotarget.
[26] H. Einsele,et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Jäger,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[28] A. Wolf,et al. Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications , 2016, Clinical Pharmacokinetics.
[29] R. Kischel,et al. Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions , 2016, Immunological reviews.
[30] F. Koinis,et al. Small cell lung cancer (SCLC): no treatment advances in recent years. , 2016, Translational lung cancer research.
[31] G. Giaccone,et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Rudin,et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.
[33] Carlos Caldas,et al. Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. , 2015, Cancer research.
[34] C. Rudin,et al. Small cell lung cancer: Where do we go from here? , 2015, Cancer.
[35] Raphael Kopan,et al. Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cells , 2012, Development.
[36] E. Kremmer,et al. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. , 2011, Human molecular genetics.
[37] R. Kischel,et al. Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA , 2009, Journal of immunotherapy.
[38] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[39] E. Kremmer,et al. Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo , 2007, The Journal of cell biology.
[40] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] P. Kufer,et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.
[42] R. Krumlauf,et al. Dynamic expression patterns of the pudgy/spondylocostal dysostosis gene Dll3 in the developing nervous system , 2001, Mechanisms of Development.
[43] H. Liu,et al. Treatment of small cell lung cancer. , 1991, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.
[44] W. Hiddemann,et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.
[45] R. Larson,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.
[46] R. G. Lacsamana,et al. Where do we go from here? , 1986, The Journal of the Florida Medical Association.